+91 9425150513 (Asia) support@24lifesciences.com
Size, Share & Industry Analysis, By Type (Spherical, Aspherical), By Application (Hospitals, Ophthalmology Clinics, Ambulatory Surgery Centers, Others), By End User (Patients with High Myopia, Patients with Astigmatism, Patients with Hyperopia), By Material Technology (Collamer-based Lenses, Silicone-based Lenses, Other Polymer Lenses), By Surgery Type (Standard ICL Implantation, Bioptic Procedures (ICL + LASIK/PRK), Lens Replacement Procedures), and Regional Forecast, 2026-2034
The global ICL Implantable Micro Lens market was valued at USD 478.2 million in 2025 and is estimated at USD 514.6 million in 2026. The market is projected to reach USD 925.2 million by 2034, representing a 7.6% CAGR during 2026–2034.
ICL implantable micro lenses are phakic intraocular lenses placed inside the eye while preserving the natural crystalline lens. They are used for refractive correction in patients with myopia, astigmatism and selected hyperopic needs, particularly where corneal laser procedures are unsuitable or where patients prefer a reversible, non-corneal-tissue-removing option. Market value includes implantable lens revenue and the device technologies captured by the report, not the full value of ophthalmic surgery services or unrelated intraocular lenses used for cataract replacement.
Demand is structurally connected to the global rise in myopia and to refractive-surgery choice. A 2025 systematic review in the British Journal of Ophthalmology estimated pooled childhood and adolescent myopia prevalence at 35.81% in 2023 and projected 39.80% by 2050. High myopia is commercially important because some patients have corneal thickness or refractive-error profiles that can make phakic lenses attractive relative to corneal laser ablation.
Regulatory expansion is widening the treated population. FDA approved an indication change in November 2025 extending EVO/EVO+ ICL/TICL use from ages 21–45 to 21–60. STAAR reported in February 2026 that more than four million ICLs had been sold worldwide. These milestones strengthen physician familiarity and expand the potential addressable population, although elective self-pay economics and surgeon selection remain central to procedure conversion.
Evidence: FDA PMA Supplement P030016/S048; STAAR Surgical — 4 Million ICLs; PubMed — Global myopia prevalence meta-analysis; STAAR Surgical 2025 Form 10-K.
The report covers implantable phakic micro lenses used for refractive correction while the natural crystalline lens remains in place. The supplied segmentation spans Type, Application, End User, Material Technology and Surgery Type. Revenue excludes routine cataract intraocular lenses, contact lenses, spectacle lenses, corneal laser equipment and the full value of surgical-provider fees.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Year | 2034 |
| Forecast Period | 2026–2034 |
| Market Size Unit | USD million |
| Geography | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| By Type | Spherical; Aspherical |
| By Application | Hospitals; Ophthalmology Clinics; Ambulatory Surgery Centers; Others |
| By End User | Patients with High Myopia; Patients with Astigmatism; Patients with Hyperopia |
| By Material Technology | Collamer-based Lenses; Silicone-based Lenses; Other Polymer Lenses |
| By Surgery Type | Standard ICL Implantation; Bioptic Procedures (ICL + LASIK/PRK); Lens Replacement Procedures |
| Key Market Players | STAAR Surgical Company; Alcon; Johnson & Johnson Vision; Bausch + Lomb; Carl Zeiss Meditec; Hoya Surgical Optics; Ophtec; Rayner; Aurolab; Lenstec; HumanOptics; Biotech Visioncare; Omni Lens; SIFI Medtech |
The market definition follows the report's commercial taxonomy even where clinical practice may use broader terms such as phakic intraocular lens. Collamer-based products are particularly associated with STAAR Surgical, while other lens manufacturers may participate through alternative phakic designs or broader ophthalmic lens portfolios.
The 2025 global systematic review of childhood and adolescent myopia found pooled prevalence rising from 24.32% in 1990 to 35.81% in 2023, with projections approaching 39.80% by 2050. Not all myopic patients are candidates for ICL surgery, but a larger high-myopia population expands the funnel for refractive evaluation, particularly among patients seeking alternatives to spectacles, contact lenses or corneal laser surgery.
FDA approved STAAR's S048 supplement on November 14, 2025, expanding the indicated age range for EVO/EVO+ ICL/TICL from 21–45 to 21–60 years. The change adds older refractive patients to the U.S. labeled population, potentially increasing procedure evaluations in established surgeon practices without requiring a new device platform.
Refractive lens implantation is frequently elective, so demand is sensitive to household confidence, financing, clinic marketing and the relative price of LASIK/PRK or premium contact lenses. STAAR's 2025 results illustrate this sensitivity: its net sales fell materially versus 2024 amid weaker China demand even as the long-term installed surgeon base remained intact. This makes geographic mix and consumer confidence important determinants of near-term market performance.
Phakic lens implantation requires anterior-segment measurement, lens sizing, vault assessment and management of intraocular surgical risks. Clinic adoption therefore depends on trained refractive surgeons and appropriate diagnostic infrastructure. Vendors that provide planning tools, education and post-market evidence can reduce adoption friction and strengthen surgeon loyalty.
Evidence: PubMed — Myopia prevalence meta-analysis; FDA — EVO ICL age expansion; STAAR Surgical 2025 Form 10-K.
STAAR's February 2026 milestone of more than four million ICLs sold globally reflects a growing installed base of trained surgeons and patients familiar with implantable refractive lenses. The core value proposition is additive and reversible correction without removing corneal tissue, which can be attractive to high-myopia patients and others who are poor laser candidates.
The FDA indication expansion to age 60 changes the commercial boundary of the U.S. EVO ICL population. Clinics can now evaluate a wider range of adult patients under the approved labeling, although presbyopia, early lens changes and individual ocular anatomy still influence suitability. Vendors and providers can tailor education to patients whose refractive goals differ from the younger LASIK population.
STAAR's 2025 Form 10-K reported USD 77.8 million of sales to two China distributors, down from USD 162.3 million in 2024, reflecting channel inventory and consumer-demand pressure. The company also accelerated commercial production in Switzerland for China. The episode shows that high underlying myopia prevalence does not automatically translate into smooth revenue growth; channel discipline and local consumer conditions matter.
STAAR reported that its Nidau, Switzerland facility began producing commercial EVO and EVO+ product in 2025 for China, partly to reduce tariff exposure. For a market concentrated around specialized optical materials and tightly controlled implant manufacturing, geographic redundancy can protect supply and support expansion without relying on a single production route.
Evidence: STAAR Surgical — 4 Million ICLs; STAAR Surgical 2025 Form 10-K; STAAR Surgical — Shareholder Letter, March 2026.
ICL adoption depends on the interaction of optical design, lens material, ocular sizing, surgical technique and post-operative monitoring. The market therefore competes on a full refractive-correction workflow rather than lens price alone.
Collamer combines a polymer matrix with a collagen-containing component and is central to STAAR's EVO ICL positioning. Material biocompatibility, optical clarity and long-term ocular performance support premium positioning and high surgeon familiarity.
The lens is positioned behind the iris and in front of the natural crystalline lens. Because the natural lens remains, the procedure preserves accommodation in appropriately selected patients and can be reversed by lens removal or exchange.
Pre-operative ocular measurements are critical to select lens power and size. Post-operative vault and intraocular pressure monitoring influence outcomes, making diagnostic workflow and surgeon experience central to adoption.
Unlike LASIK or PRK, implantable phakic lenses do not require corneal tissue removal. This can expand choice for patients with high refractive error or corneal characteristics that make laser treatment less attractive.
The report segments lenses into Spherical and Aspherical types. Spherical designs remain the established volume base, while aspherical optics address higher-order visual quality and premium outcome expectations.
Spherical ICL designs are widely used for standard refractive correction and benefit from established surgeon familiarity and historical clinical evidence. They remain a core revenue contributor where predictable power correction and broad availability outweigh demand for specialized optical profiles.
Aspherical designs seek to optimize peripheral optics and reduce spherical aberration. Adoption is supported by premium refractive clinics and patients with high visual-quality expectations, especially where night-vision performance and contrast sensitivity influence procedure choice.
As lens-based refractive correction becomes more competitive, manufacturers are expected to place greater emphasis on optical customization, toric capability, sizing accuracy and digital planning rather than relying on a single standard geometry.
The report segments applications into Hospitals, Ophthalmology Clinics, Ambulatory Surgery Centers and Others. Ophthalmology clinics hold the leading position because elective refractive procedures benefit from specialized diagnostics, surgeon concentration, patient counseling and repeatable outpatient workflows.
Specialist eye clinics concentrate refractive surgeons, corneal tomography, biometry and post-operative follow-up. High procedure focus enables standardized patient education and efficient conversion from consultation to surgery.
Hospitals remain important for patients requiring broader medical support, teaching centers and markets where refractive surgery is embedded in tertiary ophthalmology departments. Their capital base can support advanced diagnostics, although elective workflow may be less streamlined.
ASCs can offer efficient operating-room utilization and lower overhead for selected ophthalmic procedures. Growth depends on local regulation, surgeon ownership models and the ability to coordinate diagnostic assessment and post-operative follow-up outside the surgical facility.
Other channels include dedicated refractive centers and integrated private eye-care networks. Their commercial strength lies in direct-to-consumer marketing, financing and high surgeon procedure volume.
The report segments end users into patients with High Myopia, Astigmatism and Hyperopia. High-myopia patients are the core group because implantable phakic lenses can provide correction where laser tissue removal becomes less desirable or technically constrained.
High-myopia patients represent the central clinical and commercial population. Lens-based correction avoids removing corneal tissue and can deliver large refractive power through an implant, making it attractive for eyes outside comfortable laser-treatment ranges.
Toric phakic lenses combine spherical and cylindrical correction, allowing clinics to address astigmatism without relying exclusively on separate corneal procedures. Growth depends on rotational stability, accurate axis planning and surgeon confidence.
Hyperopic phakic-lens use is more selective and varies by product availability and regional labeling. Commercial opportunity is concentrated in carefully screened patients for whom other refractive options are less suitable.
The report covers Collamer-based, Silicone-based and Other Polymer lenses. Collamer-based products lead the supplied material taxonomy because of their established use in the EVO ICL platform and the large global installed base reported by STAAR.
Collamer-based lenses have the strongest brand and clinical visibility in the phakic IOL category. STAAR's four-million-lens milestone demonstrates the scale achieved by the material platform and reinforces surgeon familiarity.
Silicone optics are well established across ophthalmic lenses but play a more selective role in the phakic-lens market. Supplier differentiation depends on foldability, optical properties, long-term biocompatibility and available lens geometry.
Other hydrophilic and hydrophobic polymers support alternative phakic-lens designs and regional product portfolios. New materials must demonstrate optical stability, biocompatibility and manufacturability while navigating demanding implantable-device regulatory pathways.
The report distinguishes Standard ICL Implantation, Bioptic Procedures combining ICL with LASIK/PRK, and Lens Replacement Procedures. Standard ICL implantation remains the most prevalent route because it directly addresses refractive error while retaining the natural crystalline lens.
Standard implantation is the core procedure and supports the largest recurring lens volume. Its appeal is the additive correction of refractive error with preservation of the natural lens in appropriately selected patients.
Bioptics combine phakic lens implantation with corneal laser treatment to address residual refractive error or complex prescriptions. The pathway can expand treatment flexibility but adds planning, cost and staged-procedure considerations.
Lens replacement removes the natural crystalline lens and therefore differs clinically from standard phakic ICL implantation. It is included in the supplied report taxonomy as an adjacent surgical pathway but competes more directly with refractive lens exchange and premium IOL strategies.
North America is the largest market in the 2025 report framework, while Asia-Pacific is the fastest-growing region. Regional performance depends on refractive-surgery economics, myopia burden, surgeon training, product approvals and consumer confidence.
The United States anchors North American demand through an established refractive-surgery infrastructure, high patient awareness and a clear FDA pathway for phakic IOLs. The November 2025 EVO ICL indication expansion to age 60 creates a wider labeled patient pool and can support procedure growth in existing clinics.
Europe combines experienced refractive surgeons with country-specific regulation and self-pay procedure economics. Germany, Spain, the United Kingdom and other private ophthalmology markets support premium lens-based correction, while reimbursement is generally less important than consumer willingness to pay and clinic differentiation.
Asia-Pacific benefits from very high myopia prevalence in East Asia, large private ophthalmology networks and strong awareness of refractive correction. China remains strategically important despite recent channel volatility, while Japan and South Korea have mature premium eye-care markets.
Demand is concentrated in large urban private ophthalmology markets such as Brazil and Mexico. Procedure affordability, surgeon availability and imported-device pricing influence adoption, while premium refractive centers can create localized high-volume clusters.
Gulf markets support premium elective ophthalmology through private hospitals and medical tourism, while broader regional adoption is constrained by specialist availability and affordability. Opportunities are strongest in urban centers with refractive-surgery infrastructure.
On November 14, 2025, FDA approved STAAR's S048 supplement expanding the indicated age range for EVO/EVO+ ICL/TICL from 21–45 to 21–60. The approval supports commercial outreach to older refractive patients while maintaining the device's PMA-level regulatory framework.
ICL procedures are commonly purchased as elective refractive surgery rather than as medically necessary insured care. This places greater weight on consumer financing, clinic pricing, patient education and perceived visual-quality benefits. Reimbursement becomes more relevant only where specific medical indications or regional coverage policies apply.
Implantable phakic lenses require continued post-market monitoring of safety, effectiveness and labeling. Mature PMA history and a large commercial installed base can lower perceived adoption risk for surgeons, while new entrants must invest in long-term clinical evidence and surgeon training.
Evidence: FDA PMA Supplement P030016/S048; STAAR — 4 Million ICLs.
The competitive landscape is shaped by specialized phakic-lens intellectual property, surgeon familiarity, optical design, material technology, regulatory approvals and distribution into refractive clinics. The report profiles a broad ophthalmic company set, but current market visibility is particularly strong around dedicated phakic-lens platforms.
STAAR is the most visible dedicated phakic IOL manufacturer, with EVO ICL products representing essentially all fiscal 2025 sales and more than four million ICLs sold globally by February 2026. Its competitive moat combines proprietary material, regulatory history and a large trained-surgeon network.
Large ophthalmic companies bring surgeon relationships, capital equipment portfolios and global distribution. Their participation raises competitive expectations for integrated refractive planning and cross-selling across diagnostic and surgical workflows.
Specialist lens manufacturers compete in selected geographies through alternative phakic designs, local pricing and surgeon relationships. Regional manufacturing can improve affordability and tender responsiveness.
Alcon terminated its proposed STAAR acquisition on January 6, 2026 after the required STAAR stockholder approval was not obtained. STAAR therefore continues to compete as an independent publicly traded company.
STAAR announced that more than four million Implantable Collamer Lenses had been sold worldwide, demonstrating the scale of the installed procedure base and increasing patient familiarity with lens-based refractive correction.
STAAR did not obtain the required stockholder approval for the proposed acquisition, and Alcon terminated the merger agreement. STAAR remains a standalone company, preserving an independent competitive structure around the EVO ICL franchise.
FDA approved supplement P030016/S048, expanding the EVO/EVO+ ICL/TICL indicated age range from 21–45 to 21–60 years. The change enlarges the labeled U.S. patient pool for phakic lens correction.
STAAR reported that its Nidau facility began commercial production in 2025 and is focused on EVO/EVO+ supply for China, strengthening geographic manufacturing resilience and reducing tariff exposure.
A British Journal of Ophthalmology systematic review reported 35.81% pooled childhood/adolescent myopia prevalence in 2023 and projected 39.80% by 2050, reinforcing the long-term refractive-correction demand base.
Evidence: STAAR — 4 Million ICLs; STAAR — January 2026 Special Meeting; Alcon — Transaction Termination; FDA — P030016/S048; STAAR 2025 Form 10-K; PubMed — Myopia Meta-analysis.
The market is projected to reach USD 925.2 million by 2034 from an estimated USD 514.6 million in 2026, representing a 7.6% CAGR during 2026–2034. Growth will depend on the conversion of a large myopic population into elective surgical candidates, expansion of trained surgeon networks and broader regulatory access for current and next-generation phakic lenses.
Patients outside comfortable laser-treatment ranges remain the clearest clinical and commercial segment for phakic-lens implantation.
The U.S. EVO ICL age expansion to 60 creates new procedure opportunities within existing refractive practices.
Toric correction, optical quality, sizing accuracy and digital planning are expected to influence premium product differentiation.
Very high myopia prevalence supports long-run opportunity, while 2025 China volatility shows that inventory, consumer confidence and distributor execution remain important.
Market estimates are developed using bottom-up analysis of phakic-lens manufacturers, product portfolios, geographic sales exposure, refractive-clinic adoption and average lens values, combined with top-down analysis of myopia prevalence, refractive-surgery demand, eligible patient groups and regional access.
Primary research is used to validate procedure mix, patient selection, surgeon adoption, clinic purchasing, competitive positioning and geographic demand. Secondary research emphasizes FDA PMA records, peer-reviewed ophthalmic literature, company filings and official manufacturer disclosures. Market-research/report-selling websites are excluded from the public evidence base.
Forecast assumptions incorporate myopia prevalence, age eligibility, refractive-surgery substitution, surgeon training, product approvals, optical/material innovation, consumer affordability and regional channel conditions. Company sales are used only as competitive indicators and are not treated as total-market revenue unless the product boundary aligns directly with the report scope.
The market was valued at USD 478.2 million in 2025, is estimated at USD 514.6 million in 2026, and is projected to reach USD 925.2 million by 2034 at a 7.6% CAGR during 2026–2034.
North America is the largest market in 2025, while Asia-Pacific is expected to grow faster through the forecast period.
Ophthalmology clinics lead Application demand because they concentrate refractive surgeons, diagnostic equipment, patient counseling and outpatient procedure workflows.
Patients with high myopia form the dominant End User group because implantable phakic lenses can correct large refractive errors without removing corneal tissue.
Collamer-based lenses lead the supplied material taxonomy, supported by the large global installed base of STAAR Surgical's EVO ICL platform.
On November 14, 2025, FDA expanded the EVO/EVO+ ICL/TICL indicated age range from 21–45 to 21–60 years.
STAAR Surgical announced on February 25, 2026 that more than four million Implantable Collamer Lenses had been sold worldwide.
The report profiles STAAR Surgical, Alcon, Johnson & Johnson Vision, Bausch + Lomb, Carl Zeiss Meditec, Hoya Surgical Optics, Ophtec, Rayner, Aurolab, Lenstec, HumanOptics, Biotech Visioncare, Omni Lens and SIFI Medtech.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.
